Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGT1A1 genotype-guided irinotecan dosing study
NL-OMON22175Suspended
- Sponsor
- Catharina Ziekenhuis
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of irinotecan in colorectal cancer (CRC), pancreatic cancer (PC) and cancer (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoint: Incidence of febrile neutropenia. Started Sep 2017; status: suspended.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)cancer
Beyond the preview
Go deeper on NL-OMON22175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22175.